➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Merck
McKinsey
AstraZeneca
Moodys

Last Updated: January 16, 2021

DrugPatentWatch Database Preview

Litigation Details for CELGENE CORPORATION v. PAR PHARMACEUTICAL, INC. (D.N.J. 2017)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

CELGENE CORPORATION v. PAR PHARMACEUTICAL, INC. (D.N.J. 2017)

Docket   Start Trial Date Filed 2017-05-04
Court District Court, D. New Jersey Date Terminated 2019-02-07
Cause 35:271 Patent Infringement Assigned To Esther Salas
Jury Demand None Referred To Michael A. Hammer
Parties PAR PHARMACEUTICAL COMPANIES, INC.
Patents 6,045,501; 6,315,720; 6,561,977; 6,755,784; 8,198,262; 8,315,886; 8,626,531; 8,673,939; 8,735,428; 8,828,427; 8,927,592
Attorneys FRANK CHARLES CALVOSA
Firms Quinn Emanuel Uquhart & Sullival LLP
Link to Docket External link to docket
Small Molecule Drugs cited in CELGENE CORPORATION v. PAR PHARMACEUTICAL, INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for CELGENE CORPORATION v. PAR PHARMACEUTICAL, INC. (D.N.J. 2017)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 122 Celgene’s closely-related U.S. Patent No. 6,045,501 (“the ’501 patent”), where the PTAB concluded ….S. Patent No. 8,626,531 B1 ’720 patent U.S. Patent No. 6,315,720 B1 ’784 patent ….S. Patent No. 6,755,784 B2 ’886 patent U.S. Patent No. 8,315,886 B2 ’939 patent …MOT patents”); (2) the ’427 formulation patent; and (3) ’720, ’977, ’784, ’886, and ’531 patents, which…. The MOT Patents (’262, ’939, and ’428 Patents) The asserted MOT patent claims are generally External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Merck
McKinsey
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.